[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563539":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":45,"id":49,"slug":19,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"AdventHealth","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Open Label Main Arm","Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)",[12],"Drug: 18F-rhPSMA-7.3 (Posluma)",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","18F-rhPSMA-7.3 (Posluma)","PET Scan using Posluma for detection of early recurrence of prostate cancer.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"AdventHealth AdventHealth Oncology Research","CONTACT","407-303-2090","CFD.ResearchOncology@AdventHealth.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Orlando","Florida","32804","United States",{"type":34,"coordinates":35},"Point",[36,37],-81.37924,28.53834,{"lat":37,"lon":36},[40,41],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":42,"role":23,"phone":19,"phoneExt":19,"email":19},"Guru Sonpavde, MD, MD",{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[46],{"name":47,"class":48},"Blue Earth Diagnostics","INDUSTRY","100563539",false,"NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence","Inclusion Criteria:\n\n* History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.\n* An elevated PSA test result that is greater than or equal to 0.1 ng\u002Fml and less than 0.5\n\nExclusion Criteria:\n\n* Patients who are planned to have an x-ray contrast agent or other PET radiotracer \\& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.\n* Patients currently receiving Androgen Deprivation Therapy (ADT).","MALE","18 Years",{"count":58,"type":59},30,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.\n\nThe research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.",[65],"Prostate Cancer (Post Prostatectomy)",[67],"Rising PSA following cancer prostatectomy surgery","2024-10-22",{"date":70,"type":71},"2024-10-24","ACTUAL",{"date":73,"type":71},"2024-09-20",{"date":75,"type":59},"2027-10-10",{"name":5,"class":6},1]